Aclarion ACONW

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.01 (-10.40%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Aclarion (ACONW)
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $0.0672

  • Price-Earnings Ratio

    -0.45

  • Total Outstanding Shares

    10.05 Million Shares

  • Total Employees

    6

  • Dividend

    No dividend

  • IPO Date

    April 22, 2022

  • SIC Description

    Services-medical Laboratories

  • Primary Exchange

    NASDAQ

  • Type

    Warrant

  • Headquarters

    8181 arista place, Broomfield, CO, 80021

  • Homepage

    https://www.aclarion.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow$139,410
Net Cash Flow, Continuing$139,410
Net Cash Flow From Operating Activities, Continuing$-1.06 Million
Net Cash Flow From Operating Activities$-1.06 Million
Net Cash Flow From Investing Activities$-103,697
Net Cash Flow From Financing Activities$1.30 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Income/Loss Available To Common Stockholders, Basic$-1.38 Million
Income Tax Expense/Benefit$0
Gross Profit$-6,925
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$12,142
Income/Loss From Continuing Operations Before Tax$-1.37 Million
Net Income/Loss Attributable To Parent$-1.37 Million

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$0
Comprehensive Income/Loss$-1.38 Million
Comprehensive Income/Loss Attributable To Parent$-1.38 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Fixed Assets$892
Noncurrent Liabilities$0
Liabilities$678,267
Current Assets$1.90 Million
Assets$3.19 Million
Accounts Payable$331,765

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ACONW from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    â“’ 2025 Financhle. All Rights Reserved.